Ads
related to: multiple sclerosis treatment- Dosing & Initiation Info
Learn About First Dosing For
An RMS Treatment Option.
- View The Safety Profile
Read About The Safety Profile For
An RMS Treatment Option.
- Efficacy & Study Info
Read Compelling Efficacy Data &
Learn About An RMS Treatment Option
- Additional Studies
Read About Additional RMS Clinical
Studies On The Physician Site.
- RMS Clinical Trials
Access Trial Information & View
Clinical Endpoint Data.
- Watch Video Content
Watch Video Content For HCPs
On RMS Treatment And Efficacy.
- Dosing & Initiation Info
Search results
Black holes precipitate as dark matter
Weston Forum· 2 days agoIn order to estimate the number of primordial black holes, only theoretical calculations remain. As experts have discovered, the range could be very...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days ago- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment
Clene (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8(R) in ALS
Digital Journal· 2 days ago"CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, all while being very well-tolerated, in both of our...focused on improving ...
FSD Pharma Provides Corporate Update
Digital Journal· 4 days agoTORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of ...
D.C.’s Vanda Pharmaceuticals rejects acquisition offer — again - Washington Business Journal
The Business Journals· 3 days agoVanda Pharmaceuticals Inc. (NASDAQ: VNDA) has rejected an unsolicited acquisition proposal that...
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in...
Digital Journal· 3 days agoTORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets ...
JD Supra: EU and UK Consider First Stand-Alone Disparagement Cases
JD Supra· 2 days agoThe development of case law on disparagement has, to date, been driven mainly by the French competition authority, or has been addressed under consumer protection or other national laws. The ...
May is Better Speech and Hearing Month - The Advocate-Messenger
The Danville Advocate-Messenger· 3 days agoDo you find yourself coughing or throat clearing when eating and drinking? Do you have a wet or...
Nightmares, 'daymares' could be tell-tale signs of autoimmune disease
MedicalNewsToday via AOL· 1 day agoRecent research from the United Kingdom suggests that the onset of graphic nightmares and...
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with...
Benzinga· 6 days agoThe law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Biogen Inc. BIIB securities between February 3, 2022 and February 13, 2024, both dates inclusive (the ...
